Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104, USA.
Diabetologia. 2018 Dec;61(12):2512-2515. doi: 10.1007/s00125-018-4676-1. Epub 2018 Jun 29.
In this commentary, we describe the limitations of positron emission tomography (PET) in visualising and characterising beta cell mass in the native pancreas in healthy individuals and those diagnosed with diabetes. Imaging with PET requires a large mass of targeted cells or other structures in the range of approximately 8-10 cm. Since islets occupy only 1% of the pancreatic volume and are dispersed throughout the organ, it is our view that uptake of PET tracers, including [F]fluoropropyl-(+)-dihydrotetrabenazine, in islets cannot be successfully detected by current imaging modalities. Therefore, we dispute the feasibility of PET imaging for the detection of loss of beta cells in the native pancreas in individuals with diabetes. However, we believe this novel approach can be successfully employed to visualise beta cell mass in individuals with hyperinsulinism and transplanted islets.
在这篇评论中，我们描述了正电子发射断层扫描（PET）在观察和描述健康个体和糖尿病患者天然胰腺中β细胞质量方面的局限性。使用 PET 进行成像需要大量目标细胞或其他结构，范围约为 8-10 厘米。由于胰岛仅占胰腺体积的 1%，并且分布在整个器官中，因此我们认为，包括[F]氟丙基-（+）-二氢四苯并嗪在内的 PET 示踪剂在胰岛中的摄取目前的成像方式无法成功检测到。因此，我们怀疑 PET 成像是否可用于检测糖尿病个体中天然胰腺中β细胞的丢失。然而，我们认为这种新方法可以成功用于可视化高胰岛素血症个体和移植胰岛中的β细胞质量。
